Analysts' mean recommendation for Palatin Technologies, Inc.
Beta is also an important valuation ratio for analyzing the stock of the company, PTN has Beta of 1.36 while its industry and Sector's beta remains at 0.94 and 0.83 respectively. The current value of the RSI is 55.93 that is neither bought nor sold range. Usually the RSI is considered overbought when above 70 and oversold when less than 30.
Palatin Technologies, Inc.'s (PTN) price volatility for a month noted as 5.87% however its price volatility for a week documented as 8.45%. The company is set at a mean analysts' recommendation of 1.40.
The company reported an impressive total revenue of 0 in the last fiscal year. The Q4 2017 consensus earnings estimates for the company have stabilized at US$-0.04 per share.
The share price of the company (PTN) was up +18.74%, with a high of 0.41 during the day and the volume of Palatin Technologies, Inc. shares traded was 8799193.
Currently, the market capitalization of Palatin Technologies Inc. (NYSE: AXE), is estimated to report earnings on April 25, 2017.
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The company's stock had a trading volume of 2,516,273 shares. A simple moving average (SMA) is an mathematical moving average calculated by adding the closing price of the security for a number of time periods and then dividing this total by the number of time periods.
ATR is counted for different periods, like 9-day, 14-day, 20-day, 50-day and 100-day. It would take about 4.4 days to cover all short positions. The stock's 50 day moving average is $0.34 and its 200 day moving average is $0.47.
Palatin Technologies Inc. (PTN) has a 52-week high of $0.90 and a 52-week low of $0.29.
08/19/2015 - Palatin Technologies, Inc. had its " rating reiterated by analysts at Piper Jaffray. Analysts have a mean recommendation of 1.70 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range).
Palatin Technologies, Inc is a biopharmaceutical company. In this case, shares are down -54.36% from $0.9, the 52-week high touched on November 30, 2016, but are collecting gains at -9.89% for the past 12 months. Finally, Roth Capital restated a "buy" rating and set a $1.50 price objective on shares of Palatin Technologies in a research report on Wednesday, January 25th. Moreover, Next Generation issued Initiated rating for the stock on 23-Jan-07.
A trend analysis is a method of analysis that allows traders to predict what will happen with a stock in the future. The corporation holds 138.06 million outstanding shares and its 135.55 million shares were floated in the market. The overall volume in the last trading session was 2.28 million shares, versus the average volume of 3.44 million shares.
Looking about the past performance history, the company jumped 20.37% in past week and climbed 7.34% in one month.